Clinical Trials in Italy / NCT07582770
Starting soon
Observational
Cognitive Impairment Assessment in Breast Cancer Survivors
NCT07582770 · tracked via the Priya Life Science Italy tracker
Condition(s) studied
Cancer Related Cognitive ImpairmentBreast Cancer Survivors
Study summary
This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.
Eligibility
Inclusion Criteria:
* Age between 18 and 65 years old
* Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)
* Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)
* Understanding of the Italian language and ability to give informed consent
Exclusion Criteria:
* Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)
* Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)
* Patient with a previous diagnosis of malignant carcinomas (only for control gruop)
* Patient with a history of brain damage with unresolved neurological consequences
* Patient with previous or current serious neurological pathologies
* Patient with severe psychiatric conditions
* Patient with systemic pathologies that could interfere with cognitive abilities
* Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment
* Patient with visual or hearing impairments that are not properly corrected
* Patient with any disability that might compromise the validity of cognitive tests
Primary outcome measure(s)
- Validation of a second-level cognitive test battery to be employed for clinical use for the detection of CRCI in breast cancer survivors — At enrollment
Overall success rate to assess CRCI in breast cancer survivors compared with already existing tests.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| European Institute of Oncology | Milan | Italy |
More European Institute of Oncology trials in Italy
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07582770 on ClinicalTrials.gov ↗ ← All trials in Italy